Incidence of symptomatic vertebral fracture with high-dose glucocorticoid treatment in the Chiba-Shimoshizu Rheumatic Cohort between 1986 and 2006

Endocrine Journal

Volumn 56, Issue 4, 2009, Pages 591-599

  Sugiyama, Takao ^a,c   Tatsuno, Ichiro ^b,c   Suzuki, Sawako ^b,c   Yoshida, Tomohiko ^b,c   Tanaka, Tomoaki ^b,c   Sueishi, Makoto ^b,c   Saito, Yasushi ^b,c  

^a SHIMOSHIZU HOSPITAL   (Japan)

^b CHIBA UNIVERSITY HOSPITAL   (Japan)

^c CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Collagen vascular disease; Glucocorticoid; Osteoporosis; Symptomatic vertebral fracture

Indexed keywords

GLUCOCORTICOID; PREDNISOLONE;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG MEGADOSE; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; POLYMYOSITIS; RHEUMATOID ARTHRITIS; RISK FACTOR; SEX DIFFERENCE; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; VERTEBRA FRACTURE; WEGENER GRANULOMATOSIS;

ADULT; AGED; COHORT STUDIES; COLLAGEN DISEASES; FEMALE; GLUCOCORTICOIDS; HUMANS; INCIDENCE; JAPAN; MALE; MIDDLE AGED; PREDNISOLONE; RISK FACTORS; SPINAL FRACTURES;

EID: 68449099557     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K08E-318     Document Type: Article

References (47)

1. Cushing H (1932) The basophilic adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp 1:137-192.
2. Canalis E, Bilezikian JP, Angeli A, Giustina A (2004) Perspectives on glucocorticoid-induced osteoporosis. Bone 34:593-598
3. Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319-1328.
4. Manelli F, Giustina A (2000) Glucocorticoid-induced osteoporosis. Trends Endocrinol Metab 11:79-85.
5. Mazziotti G, Angeli A, Bilezikian JP, Canalis E, Giustina A (2006) Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab 17:144-149
6. Shaker JL, Lukert BP (2005) Osteoporosis associated with excess glucocorticoids. Endocrinol Metab Clin North Am 34:341-356, viii-ix.
7. van Staa TP (2006) The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 79:129-137 (Pubitemid 44440440)
8. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993-1000. (Pubitemid 30350061)
9. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Mejia JC, Aydintug AO, Chwalinska-Sadowska H, de Ramon E, Fernandez-Nebro A, Galeazzi M, Valen M, Mathieu A, Houssiau F, Caro N, Alba P, Ramos-Casals M, Ingelmo M, Hughes GR (2003) Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82:299-308. (Pubitemid 37229465)
10. Jardinet D, Lefebvre C, Depresseux G, Lambert M, Devogelaer JP, Houssiau FA (2000) Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients: deleterious role of glucocorticoid therapy at the lumbar spine. Rheumatology (Oxford) 39:389-392 (Pubitemid 30307324)
11. Langford CA (1997) Chronic immunosuppressive therapy for systemic vasculitis. Curr Opin Rheumatol 9:41-47 (Pubitemid 27217768)
12. Nagai S, Izumi T (1997) Immunopathology of collagen vascular disease. Curr Opin Pulm Med 3:356-360
13. Ramsey-Goldman R, Dunn JE, Huang CF, Dunlop D, Rairie JE, Fitzgerald S, Manzi S (1999) Frequency of fractures in women with systemic lupus erythematosus: comparison with united States population data. Arthritis Rheum 42:882-890 (Pubitemid 29214998)
14. Sinigaglia L, Varenna M, Girasole G, Bianchi G (2006) epidemiology of osteoporosis in rheumatic diseases. Rheum Dis Clin North Am 32:631-658
15. Yee CS, Crabtree N, Skan J, Amft N, Bowman S, Situnayake D, Gordon C (2005) Prevalence and predictors of fragility fractures in systemic lupus erythematosus. Ann Rheum Dis 64:111-113 (Pubitemid 40075285)
16. Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137-1148 (Pubitemid 23261108)
17. Chatham WW, Kimberly RP (2001) Treatment of lupus with corticosteroids. Lupus 10:140-147
18. Parker BJ, Bruce IN (2007) High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus. Lupus 16:387-393
19. Naganathan V, Jones G, Nash P, Nicholson G, Eisman J, Sambrook PN (2000) Vertebral fracture risk with long-term corticosteroid therapy: prevalence and relation to age, bone density, and corticosteroid use. Arch Intern Med 160:2917-2922 (Pubitemid 32009048)
20. van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777-787
21. Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton IL, Tenenhouse A, Reeve J, Silman AJ, Pols HA, Eisman JA, McCloskey EV, Mellstrom D (2004) a meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19:893-899 (Pubitemid 41103445)
22. Peel NF, Moore DJ, Barrington NA, Bax DE, Eastell R (1995) Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheum Dis 54:801-806
23. Tatsuno I, Sugiyama T, Suzuki S, Yoshida T, Tanaka T, Sueishi M, Saito Y (2009) Age-dependent early complication of symptomatic vertebral fracture with high-dose glucocorticoid in treatment for collagen vascular diseases. J Clin Endocrinol Metab (in press).
24. Michel BA, Bloch DA, Wolfe F, Fries JF (1993) Fractures in rheumatoid arthritis: an evaluation of associated risk factors. J Rheumatol 20:1666-1669 (Pubitemid 24017566)
25. Adachi JD, Ioannidis G, Pickard L, Berger C, Prior JC, Joseph L, Hanley DA, Olszynski WP, Murray TM, Anastassiades T, Hopman W, Brown JP, Kirkland S, Joyce C, Papaioannou A, Poliquin S, Tenenhouse A, Papadimitropoulos EA (2003) The association between osteoporotic fractures and health-related quality of life as measured by the health utilities index in the canadian multicentre osteoporosis Study (CaMos). Osteoporos Int 14:895-904. (Pubitemid 38009529)
26. De Laet CE, Van Hout BA, Burger H, Weel AE, Hofman A, Pols HA (1998) Hip fracture prediction in elderly men and women: validation in the rotterdam study. J Bone Miner Res 13:1587-1593 (Pubitemid 28465299)
27. Johansson C, Black D, Johnell O, Oden A, Mellstrom D (1998) Bone mineral density is a predictor of survival. Calcif Tissue Int 63:190-196 (Pubitemid 28387969)
28. Jones G, Nguyen T, Sambrook PN, Kelly PJ, Gilbert C, Eisman JA (1994) Symptomatic fracture incidence in elderly men and women: the dubbo osteoporosis epidemiology Study (DOES). Osteoporos Int 4:277-282 (Pubitemid 24291436)
29. rd, Crowson CS, O'Fallon WM, Wahner HW, Riggs BL (2003) Relative contributions of bone density, bone turnover, and clinical risk factors to long-term fracture prediction. J Bone Miner Res 18:312-318
30. O'neill TW, Felsenberg D, Varlow J, Cooper C, Kanis JA, Silman AJ (1996) The prevalence of vertebral deformity in european men and women: the european Vertebral osteoporosis Study. J Bone Miner Res 11:1010-1018
31. Tatsuno I, Suzuki S, Yoshida T, Tanaka T, Sueishi M, Sugiyama T (2009) High prevalence and early complication of symptomatic vertebral fracture in the elderly treated with high-dose glucocorticoids. J Am Geriatr Soc 57:188-189
32. Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, Dalsky GP, Marcus R (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028-2039
33. De Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, Van Staa TP (2007) Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 56:208-214 (Pubitemid 46106193)
34. Lekamwasam S, Trivedi DP, Khaw KT (2002) An association between respiratory function and bone mineral density in women from the general community: a cross sectional study. Osteoporos Int 13:710-715 (Pubitemid 35000998)
35. Romas E (2005) Bone loss in inflammatory arthritis: mechanisms and therapeutic approaches with bisphosphonates. Best Pract Res Clin Rheumatol 19:1065-1079 (Pubitemid 41748514)
36. Sin DD, Man JP, Man SF (2003) The risk of osteoporosis in caucasian men and women with obstructive airways disease. Am J Med 114:10-14 (Pubitemid 36126509)
37. van Hogezand RA, Hamdy NA (2006) Skeletal morbidity in inflammatory bowel disease. Scand J Gastroenterol Suppl 59-64. (Pubitemid 43941067)
38. Dykman TR, Gluck OS, Murphy WA, Hahn TJ, Hahn BH (1985) Evaluation of factors associated with glucocorticoid- induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 28:361-368
39. McEvoy CE, Ensrud KE, Bender E, Genant HK, Yu W, Griffith JM, Niewoehner DE (1998) Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157:704-709 (Pubitemid 28150676)
40. Walsh LJ, Wong CA, Oborne J, Cooper S, Lewis SA, Pringle M, Hubbard R, Tattersfield AE (2001) Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax 56:279-284 (Pubitemid 32269807)
41. Kingery WS (1997) A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes. Pain 73:123-139
42. Lussier D, Huskey AG, Portenoy RK (2004) Adjuvant analgesics in cancer pain management. Oncologist 9:571-591 (Pubitemid 39332322)
43. Kingery WS, Castellote JM, Maze M (1999) Methylprednisolone prevents the development of autotomy and neuropathic edema in rats, but has no effect on nociceptive thresholds. Pain 80:555-566
44. Angeli A, Guglielmi G, Dovio A, Capelli G, de Feo D, Giannini S, Giorgino R, Moro L, Giustina A (2006) High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 39:253-259 (Pubitemid 43870263)
45. de Nijs RN, Jacobs JW, Lems WF, Laan F, Algra A, Huisman AM, Buskens E, de Laet CE, Oostveen AC, Geusens PP, Bruyn GA, Dijkmans BA, Bijlsma JW (2006) Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 355:675-684
46. Compston J (2004) US and UK guidelines for glucocorticoid- induced osteoporosis: similarities and differences. Curr Rheumatol Rep 6:66-69
47. Nawata H, Soen S, Takayanagi R, Tanaka I, Takaoka K, Fukunaga M, Matsumoto T, Suzuki Y, Tanaka H, Fujiwara S, Miki T, Sagawa A, Nishizawa Y, Seino Y (2005) Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and mineral research (2004). J Bone Miner Metab 23:105-109 (Pubitemid 40591032)